Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.
You may also be interested in...
NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval
NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.